INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52101, 3, 'Fluorouracil', 'Hemorrhage', 'Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia.  Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies.  Therapy with 5- FU should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52102, 13249, 'Fluorouracil', 'Hemorrhage', 'Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia.  Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies.  Therapy with 5- FU should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52103, 17731, 'Fluorouracil', 'Hemorrhage', 'Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia.  Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies.  Therapy with 5- FU should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52104, 18740, 'Fluorouracil', 'Hemorrhage', 'Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia.  Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies.  Therapy with 5- FU should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52105, 23363, 'Fluorouracil', 'Hemorrhage', 'Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia.  Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies.  Therapy with 5- FU should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52106, 28886, 'Fluorouracil', 'Hemorrhage', 'Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia.  Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies.  Therapy with 5- FU should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52107, 3, 'Fluorouracil', 'Coronary Artery Disease', 'Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports.  Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease.  Caution and monitoring is advised in patients with coronary artery disease.  Treatment should be discontinued for cardiotoxicity.  The risks of treatment resumption after cardiotoxicity has been resolved have not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52108, 13249, 'Fluorouracil', 'Coronary Artery Disease', 'Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports.  Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease.  Caution and monitoring is advised in patients with coronary artery disease.  Treatment should be discontinued for cardiotoxicity.  The risks of treatment resumption after cardiotoxicity has been resolved have not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52109, 17731, 'Fluorouracil', 'Coronary Artery Disease', 'Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports.  Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease.  Caution and monitoring is advised in patients with coronary artery disease.  Treatment should be discontinued for cardiotoxicity.  The risks of treatment resumption after cardiotoxicity has been resolved have not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52110, 18740, 'Fluorouracil', 'Coronary Artery Disease', 'Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports.  Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease.  Caution and monitoring is advised in patients with coronary artery disease.  Treatment should be discontinued for cardiotoxicity.  The risks of treatment resumption after cardiotoxicity has been resolved have not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52111, 23363, 'Fluorouracil', 'Coronary Artery Disease', 'Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports.  Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease.  Caution and monitoring is advised in patients with coronary artery disease.  Treatment should be discontinued for cardiotoxicity.  The risks of treatment resumption after cardiotoxicity has been resolved have not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52112, 28886, 'Fluorouracil', 'Coronary Artery Disease', 'Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports.  Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease.  Caution and monitoring is advised in patients with coronary artery disease.  Treatment should be discontinued for cardiotoxicity.  The risks of treatment resumption after cardiotoxicity has been resolved have not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52113, 3433, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52114, 4861, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52115, 5026, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52116, 5029, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52117, 5039, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52118, 9138, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52119, 13870, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52120, 17273, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52121, 17971, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52122, 18156, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52123, 19154, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52124, 19235, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52125, 19237, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52126, 24087, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52127, 24885, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52128, 24886, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52129, 24887, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52130, 25454, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52131, 3433, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52132, 4861, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52133, 5026, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52134, 5029, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52135, 5039, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52136, 9138, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52137, 13870, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52138, 17273, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52139, 17971, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52140, 18156, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52141, 19154, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52142, 19235, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52143, 19237, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52144, 24087, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52145, 24885, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52146, 24886, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52147, 24887, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52148, 25454, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52149, 3433, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52150, 4861, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52151, 5026, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52152, 5029, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52153, 5039, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52154, 9138, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52155, 13870, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52156, 17273, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52157, 17971, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52158, 18156, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52159, 19154, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52160, 19235, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52161, 19237, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52162, 24087, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52163, 24885, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52164, 24886, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52165, 24887, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52166, 25454, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52167, 3433, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52168, 4861, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52169, 5026, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52170, 5029, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52171, 5039, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52172, 9138, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52173, 13870, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52174, 17273, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52175, 17971, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52176, 18156, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52177, 19154, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52178, 19235, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52179, 19237, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52180, 24087, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52181, 24885, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52182, 24886, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52183, 24887, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52184, 25454, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52185, 3433, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52186, 4861, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52187, 5026, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52188, 5029, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52189, 5039, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52190, 9138, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52191, 13870, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52192, 17273, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52193, 17971, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52194, 18156, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52195, 19154, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52196, 19235, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52197, 19237, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52198, 24087, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52199, 24885, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52200, 24886, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', '', 'DDInter', 0);
